Director/PDMR Shareholding

RNS Number : 5035O

Venture Life Group PLC

10 June 2022

 

10 June 2022

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Director/PDMR Shareholding

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that Paul McGreevy, Non-Executive Chairman, today purchased 138,571 ordinary shares of 0.3p each in the Company ("Ordinary Shares") at 35 pence per Ordinary Share.

Following this purchase, Mr Mcgreevy beneficially holds 287,439 Ordinary Shares representing approximately 0.23 per cent. of the Company's issued share capital.

For further information, please contact:

Venture Life Group PLC      [phone]

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

Cenkos Securities plc (Nomad and Joint Broker)     [phone]

Stephen Keys / Camilla Hume (Corporate Finance)

Russell Kerr / Michael Johnson (Sales)

Singer Capital Markets (Joint Broker)

Shaun Dobson / Alaina Wong  (Corporate Finance)   [phone]

Jonathan Dighe (Sales)

About Venture Life ( www.venture-life.com )

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Paul McGreevy
2	Reason for the notification
a)	Position/status	Non-Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Venture Life Group plc
b)	LEI	213800S8CZUPLAB2KC70
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 0.3p each in Venture Life Group plc GB00BFPM8908
b)	Nature of the transaction	Purchase of ordinary shares
c)	Price(s) and volume(s)	Volume Price 100,000 35.00p 38,571 35.00p
d)	Aggregated information - Aggregated volume - Price	138,571 Ordinary Shares at a volume weighted average price of 35.00 pence per Ordinary Share
e)	Date of the transaction	10 June 2022
f)	Place of the transaction	London Stock Exchange

 

END

 

 

DSHFLFLLRAIILIF